Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Myelodysplastic Syndromes 8Leukemia, Myeloid, Acute 8Multiple Myeloma 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Hematologic Neoplasms 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Hodgkin Disease 5Waldenstrom Macroglobulinemia 4Myeloproliferative Disorders 4Lymphoma, Non-Hodgkin 4Leukemia, Lymphocytic, Chronic, B-Cell 4Lymphoma, Mantle-Cell 3Lymphoma, Large B-Cell, Diffuse 3Recurrence 2Primary Myelofibrosis 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Myelodysplastic-Myeloproliferative Diseases 2Lymphoma 2Leukemia, Prolymphocytic 2Leukemia, Myelomonocytic, Chronic 2Graft vs Host Disease 2Burkitt Lymphoma 2Bronchiolitis Obliterans Syndrome 2Anemia, Aplastic 2Urologic Neoplasms 1Thyroid Neoplasms 1Thrombocythemia, Essential 1Soft Tissue Neoplasms 1Sezary Syndrome 1

Interventions

AZD 6244 7trametinib 4mirdametinib 2fludarabine 2Inhalation 2Acetylcysteine 2thymoglobulin 1talimogene laherparepvec 1omipalisib 1lorlatinib 1fludarabine phosphate 1encorafenib 1dabrafenib 1binimetinib 1abemaciclib 1Vincristine 1Specimen Handling 1Sirolimus 1Rituximab 1Radiation 1N-monoacetylcystine 1Melphalan 1Magnetic Resonance Spectroscopy 1Levetiracetam 1Lasers, Solid-State 1Lasers 1Injections 1Deoxycholic Acid 1Cytarabine 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neurofibromatosis 1 × Sirolimus × 90 days × Clear all
NCT03433183 2026-05-27

SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors

Sarcoma Alliance for Research through Collaboration

Phase 2 Completed
21 enrolled 12 charts
CNSSarcoma

Neurofibromatosis 1, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡